Evidence map›Paper›PMID 32859199›Full record

ArticleMalaria journal2020

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose.

Wei-Chiao Huang, Bingbing Deng, Moustafa T Mabrouk, Amal Seffouh, Joaquin Ortega, Carole Long, Kazutoyo Miura, Yimin Wu, Jonathan F Lovell

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The Virtues and Vices of Pfs230: From Vaccine Concept to Vaccine Candidate.The American journal of tropical medicine and hygiene · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Wei-Chiao HuangDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Bingbing DengLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
Moustafa T MabroukDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA.
Amal SeffouhDepartment of Anatomy and Cell Biology, McGill University Montreal, Quebec, H3A 0C7, Canada.
Joaquin OrtegaDepartment of Anatomy and Cell Biology, McGill University Montreal, Quebec, H3A 0C7, Canada.
Carole LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20852, USA.
Yimin WuPATH's Malaria Vaccine Initiative (MVI), Washington, DC, 20001, USA.
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, 14260, USA. jflovell@buffalo.edu.ORCID http://orcid.org/0000-0002-9052-884X
National Institutes of Health · USUniversity at Buffalo, State University of New York · USMcGill University · CAU.S. President's Malaria Initiative · US

Funding

Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria VaccineR01AI148557 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JULIEN, JEAN-PHILIPPE, LOVELL, JONATHAN F · 2020 to 2024
$2.1M
A His-tag Binding Membrane System for Generating Neutralizing Gp41 MPER antibodiesR21AI122964 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2016 to 2017
$436k
NIAID NIH HHS R01 AI148557NIAID NIH HHS R21 AI122964NIH HHS R01AI148557NIH HHS R21AI122964
6 · The paper itself

Abstract

backgroundThe Plasmodium falciparum sexual-stage surface proteins Pfs25 and Pfs230 are antigen candidates for a malaria transmission-blocking vaccine (TBV), and have been widely investigated as such. It is not clear whether simultaneously presenting these two antigens in a particulate vaccine would enhance the transmission reducing activity (TRA) of induced antibodies. To assess this, immunization was carried out with liposomes containing synthetic lipid adjuvant monophosphoryl lipid A (MPLA), and cobalt-porphyrin-phospholipid (CoPoP), which rapidly converts recombinant, his-tagged antigens into particles.

methodsHis-tagged, recombinant Pfs25 and Pfs230C1 were mixed with CoPoP liposomes to form a bivalent vaccine. Antigens were fluorescently labelled to infer duplex particleization serum-stability and binding kinetics using fluorescence resonance energy transfer. Mice and rabbits were immunized with individual or duplexed particleized Pfs25 and Pfs230C1, at fixed total antigen doses. The resulting antibody responses were assessed for magnitude and TRA.

resultsPfs230C1 and Pfs25 rapidly bound CoPoP liposomes to form a serum-stable, bivalent particle vaccine. In mice, immunization with 5 ng of total antigen (individual antigen or duplexed) elicited functional antibodies against Pfs25 and Pfs230. Compared to immunization with the individual antigen, Pfs25 antibody production was moderately lower for the bivalent CoPoP vaccine, whereas Pfs230C1 antibody production was not impacted. All antibodies demonstrated at least 92% inhibition in oocyst density at 750 μg/mL purified mouse IgG in the standard membrane feeding assay (SMFA). At lower IgG concentrations, the bivalent vaccine did not improve TRA; antibodies induced by particleized Pfs25 alone showed stronger function in these conditions. In rabbits, immunization with a 20 µg total antigen dose with the duplexed antigens yielded similar antibody production against Pfs25 and Pfs230 compared to immunization with a 20 µg dose of individual antigens. However, no enhanced TRA was observed with duplexing.

conclusionsPfs25, Pfs230 or the duplexed combination can readily be prepared as particulate vaccines by mixing CoPoP liposomes with soluble, recombinant antigens. This approach induces potent transmission-reducing antibodies following immunization in mice and rabbits. Immunization with bivalent, particleized, Pfs230 and Pfs25 did not yield antibodies with superior TRA compared to immunization with particleized Pfs25 as a single antigen. Altogether, duplexing antigens is straightforward and effective using CoPoP liposomes, but is likely to be more useful for targeting distinct parasite life stages.

Indexed as

ImmunizationAdjuvants, ImmunologicAnimalsFemaleInjections, IntramuscularLipid ALiposomesMalaria, FalciparumMalaria VaccinesMiceRabbitsAdjuvants, ImmunologicLipid ALiposomesMalaria Vaccinesmonophosphoryl lipid ALiposomesMalariaPfs230Pfs25Transmission-blocking vaccine

Identifiers

PMID32859199
PMCPMC7453371
OpenAlexW3082923610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.